2.4.0.8 Html 123 205 1 true 17 0 false 4 false false R1.htm 000010 - Document - Document and Entity Information Sheet http://signpathpharma.com/20140331/role/idr_DocumentDocumentAndEntityInformation Document and Entity Information true false R2.htm 000020 - Statement - Balance Sheets Sheet http://signpathpharma.com/20140331/role/idr_BalanceSheets Balance Sheets false false R3.htm 000030 - Statement - Balance Sheets Parenthetical Sheet http://signpathpharma.com/20140331/role/idr_BalanceSheetsParenthetical Balance Sheets Parenthetical false false R4.htm 000040 - Statement - Statements of Operations Sheet http://signpathpharma.com/20140331/role/idr_StatementsOfOperations Statements of Operations false false R5.htm 000050 - Statement - Statements of Stockholders' Equity Sheet http://signpathpharma.com/20140331/role/idr_StatementsOfStockholdersEquity Statements of Stockholders' Equity false false R6.htm 000070 - Statement - Statements of Cash Flows Sheet http://signpathpharma.com/20140331/role/idr_StatementsOfCashFlows Statements of Cash Flows false false R7.htm 000080 - Disclosure - Note 1 - Nature of Operations Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote1NatureOfOperations Note 1 - Nature of Operations false false R8.htm 000090 - Disclosure - Note 2 - Going Concern Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote2GoingConcern Note 2 - Going Concern false false R9.htm 000100 - Disclosure - Note 3 - Summary of Significant Accounting Policies Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote3SummaryOfSignificantAccountingPolicies Note 3 - Summary of Significant Accounting Policies false false R10.htm 000110 - Disclosure - Note 4 - Equipment Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote4Equipment Note 4 - Equipment false false R11.htm 000120 - Disclosure - Note 5 - Accrued Liabilities Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote5AccruedLiabilities Note 5 - Accrued Liabilities false false R12.htm 000130 - Disclosure - Note 6 - Note Payable Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote6NotePayable Note 6 - Note Payable false false R13.htm 000140 - Disclosure - Note 7 - Derivative Liability and Fair Value Measurements Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote7DerivativeLiabilityAndFairValueMeasurements Note 7 - Derivative Liability and Fair Value Measurements false false R14.htm 000150 - Disclosure - Note 8 - Stock Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote8Stock Note 8 - Stock false false R15.htm 000160 - Disclosure - Warrants Sheet http://signpathpharma.com/20140331/role/idr_DisclosureWarrants Warrants false false R16.htm 000170 - Disclosure - Stock Options Sheet http://signpathpharma.com/20140331/role/idr_DisclosureStockOptions Stock Options false false R17.htm 000180 - Disclosure - Note 11 - Income Taxes Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote11IncomeTaxes Note 11 - Income Taxes false false R18.htm 000190 - Disclosure - Note 12 - Related Party Transactions Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote12RelatedPartyTransactions Note 12 - Related Party Transactions false false R19.htm 000200 - Disclosure - Subsequent Events Sheet http://signpathpharma.com/20140331/role/idr_DisclosureSubsequentEvents Subsequent Events false false R20.htm 000210 - Disclosure - Note 9 - Common Stock Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote9CommonStock Note 9 - Common Stock false false R21.htm 000220 - Disclosure - Note 3 - Summary of Significant Accounting Policies: Use of Estimates (Policies) Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote3SummaryOfSignificantAccountingPoliciesUseOfEstimatesPolicies Note 3 - Summary of Significant Accounting Policies: Use of Estimates (Policies) false false R22.htm 000230 - Disclosure - Note 3 - Summary of Significant Accounting Policies: Accounting Basis (Policies) Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote3SummaryOfSignificantAccountingPoliciesAccountingBasisPolicies Note 3 - Summary of Significant Accounting Policies: Accounting Basis (Policies) false false R23.htm 000240 - Disclosure - Note 3 - Summary of Significant Accounting Policies: Cash and Cash Equivalents (Policies) Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote3SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsPolicies Note 3 - Summary of Significant Accounting Policies: Cash and Cash Equivalents (Policies) false false R24.htm 000250 - Disclosure - Note 3 - Summary of Significant Accounting Policies: Concentration of Credit Risk (Policies) Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote3SummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskPolicies Note 3 - Summary of Significant Accounting Policies: Concentration of Credit Risk (Policies) false false R25.htm 000260 - Disclosure - Note 3 - Summary of Significant Accounting Policies: Property and Equipment (Policies) Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote3SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentPolicies Note 3 - Summary of Significant Accounting Policies: Property and Equipment (Policies) false false R26.htm 000270 - Disclosure - Note 3 - Summary of Significant Accounting Policies: Fair Value of Financial Instruments (Policies) Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote3SummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsPolicies Note 3 - Summary of Significant Accounting Policies: Fair Value of Financial Instruments (Policies) false false R27.htm 000280 - Disclosure - Note 3 - Summary of Significant Accounting Policies: Derivative Financial Instruments (Policies) Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote3SummaryOfSignificantAccountingPoliciesDerivativeFinancialInstrumentsPolicies Note 3 - Summary of Significant Accounting Policies: Derivative Financial Instruments (Policies) false false R28.htm 000290 - Disclosure - Note 3 - Summary of Significant Accounting Policies: Research and Development Costs (Policies) Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote3SummaryOfSignificantAccountingPoliciesResearchAndDevelopmentCostsPolicies Note 3 - Summary of Significant Accounting Policies: Research and Development Costs (Policies) false false R29.htm 000300 - Disclosure - Note 3 - Summary of Significant Accounting Policies: Stock-based Compensation (Policies) Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote3SummaryOfSignificantAccountingPoliciesStockBasedCompensationPolicies Note 3 - Summary of Significant Accounting Policies: Stock-based Compensation (Policies) false false R30.htm 000310 - Disclosure - Note 3 - Summary of Significant Accounting Policies: Income Taxes (Policies) Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote3SummaryOfSignificantAccountingPoliciesIncomeTaxesPolicies Note 3 - Summary of Significant Accounting Policies: Income Taxes (Policies) false false R31.htm 000320 - Disclosure - Note 3 - Summary of Significant Accounting Policies: Basic and Diluted Net Income (loss) Per Share (Policies) Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote3SummaryOfSignificantAccountingPoliciesBasicAndDilutedNetIncomeLossPerSharePolicies Note 3 - Summary of Significant Accounting Policies: Basic and Diluted Net Income (loss) Per Share (Policies) false false R32.htm 000330 - Disclosure - Note 3 - Summary of Significant Accounting Policies: Recent Accounting Pronouncements (Policies) Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote3SummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsPolicies Note 3 - Summary of Significant Accounting Policies: Recent Accounting Pronouncements (Policies) false false R33.htm 000340 - Disclosure - Note 3 - Summary of Significant Accounting Policies: Fair Value of Financial Instruments: Fair Value, Liabilities Measured on Recurring Basis (Tables) Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote3SummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsFairValueLiabilitiesMeasuredOnRecurringBasisTables Note 3 - Summary of Significant Accounting Policies: Fair Value of Financial Instruments: Fair Value, Liabilities Measured on Recurring Basis (Tables) false false R34.htm 000350 - Disclosure - Note 3 - Summary of Significant Accounting Policies: Fair Value of Financial Instruments: Level 3 Valuation Reconciliation (Tables) Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote3SummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsLevel3ValuationReconciliationTables Note 3 - Summary of Significant Accounting Policies: Fair Value of Financial Instruments: Level 3 Valuation Reconciliation (Tables) false false R35.htm 000360 - Disclosure - Note 4 - Equipment: Property, Plant and Equipment (Tables) Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote4EquipmentPropertyPlantAndEquipmentTables Note 4 - Equipment: Property, Plant and Equipment (Tables) false false R36.htm 000370 - Disclosure - Note 7 - Derivative Liability and Fair Value Measurements: Fair value of the preferred stock (Tables) Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote7DerivativeLiabilityAndFairValueMeasurementsFairValueOfThePreferredStockTables Note 7 - Derivative Liability and Fair Value Measurements: Fair value of the preferred stock (Tables) false false R37.htm 000380 - Disclosure - Warrants: Schedule of Stockholders' Equity Note, Warrants or Rights (Tables) Sheet http://signpathpharma.com/20140331/role/idr_DisclosureWarrantsScheduleOfStockholdersEquityNoteWarrantsOrRightsTables Warrants: Schedule of Stockholders' Equity Note, Warrants or Rights (Tables) false false R38.htm 000390 - Disclosure - Note 11 - Income Taxes: Schedule of Deferred Tax Assets and Liabilities (Tables) Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote11IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesTables Note 11 - Income Taxes: Schedule of Deferred Tax Assets and Liabilities (Tables) false false R39.htm 000400 - Disclosure - Note 11 - Income Taxes: Schedule of Effective Income Tax Rate Reconciliation (Tables) Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote11IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationTables Note 11 - Income Taxes: Schedule of Effective Income Tax Rate Reconciliation (Tables) false false R40.htm 000410 - Disclosure - Note 3 - Summary of Significant Accounting Policies: Fair Value of Financial Instruments: Schedule of derivative instruments (Tables) Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote3SummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsScheduleOfDerivativeInstrumentsTables Note 3 - Summary of Significant Accounting Policies: Fair Value of Financial Instruments: Schedule of derivative instruments (Tables) false false R41.htm 000420 - Disclosure - Note 4 - Equipment: ScheduleOfPropertyAndEquipment (Tables) Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote4EquipmentScheduleOfPropertyAndEquipmentTables Note 4 - Equipment: ScheduleOfPropertyAndEquipment (Tables) false false R42.htm 000430 - Disclosure - Note 1 - Nature of Operations (Details) Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote1NatureOfOperationsDetails Note 1 - Nature of Operations (Details) false false R43.htm 000440 - Disclosure - Note 2 - Going Concern (Details) Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote2GoingConcernDetails Note 2 - Going Concern (Details) false false R44.htm 000450 - Disclosure - Note 3 - Summary of Significant Accounting Policies: Concentration of Credit Risk (Details) Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote3SummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails Note 3 - Summary of Significant Accounting Policies: Concentration of Credit Risk (Details) false false R45.htm 000460 - Disclosure - Note 3 - Summary of Significant Accounting Policies: Fair Value of Financial Instruments: Fair Value, Liabilities Measured on Recurring Basis (Details) Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote3SummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsFairValueLiabilitiesMeasuredOnRecurringBasisDetails Note 3 - Summary of Significant Accounting Policies: Fair Value of Financial Instruments: Fair Value, Liabilities Measured on Recurring Basis (Details) false false R46.htm 000470 - Disclosure - Note 3 - Summary of Significant Accounting Policies: Fair Value of Financial Instruments: Level 3 Valuation Reconciliation (Details) Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote3SummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsLevel3ValuationReconciliationDetails Note 3 - Summary of Significant Accounting Policies: Fair Value of Financial Instruments: Level 3 Valuation Reconciliation (Details) false false R47.htm 000480 - Disclosure - Note 3 - Summary of Significant Accounting Policies: Research and Development Costs (Details) Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote3SummaryOfSignificantAccountingPoliciesResearchAndDevelopmentCostsDetails Note 3 - Summary of Significant Accounting Policies: Research and Development Costs (Details) false false R48.htm 000490 - Disclosure - Note 3 - Summary of Significant Accounting Policies: Basic and Diluted Net Income (loss) Per Share (Details) Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote3SummaryOfSignificantAccountingPoliciesBasicAndDilutedNetIncomeLossPerShareDetails Note 3 - Summary of Significant Accounting Policies: Basic and Diluted Net Income (loss) Per Share (Details) false false R49.htm 000500 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details) Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote3SummaryOfSignificantAccountingPoliciesDetails Note 3 - Summary of Significant Accounting Policies (Details) false false R50.htm 000510 - Disclosure - Note 4 - Equipment (Details) Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote4EquipmentDetails Note 4 - Equipment (Details) false false R51.htm 000520 - Disclosure - Note 4 - Equipment: Property, Plant and Equipment (Details) Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote4EquipmentPropertyPlantAndEquipmentDetails Note 4 - Equipment: Property, Plant and Equipment (Details) false false R52.htm 000530 - Disclosure - Note 5 - Accrued Liabilities (Details) Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote5AccruedLiabilitiesDetails Note 5 - Accrued Liabilities (Details) false false R53.htm 000540 - Disclosure - Note 6 - Note Payable (Details) Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote6NotePayableDetails Note 6 - Note Payable (Details) false false R54.htm 000550 - Disclosure - Note 7 - Derivative Liability and Fair Value Measurements (Details) Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote7DerivativeLiabilityAndFairValueMeasurementsDetails Note 7 - Derivative Liability and Fair Value Measurements (Details) false false R55.htm 000560 - Disclosure - Note 7 - Derivative Liability and Fair Value Measurements: Fair value of the preferred stock (Details) Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote7DerivativeLiabilityAndFairValueMeasurementsFairValueOfThePreferredStockDetails Note 7 - Derivative Liability and Fair Value Measurements: Fair value of the preferred stock (Details) false false R56.htm 000570 - Disclosure - Note 8 - Stock: Preferred Stock (Details) Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote8StockPreferredStockDetails Note 8 - Stock: Preferred Stock (Details) false false R57.htm 000580 - Disclosure - Note 8 - Stock: Common Stock (Details) Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote8StockCommonStockDetails Note 8 - Stock: Common Stock (Details) false false R58.htm 000590 - Disclosure - Warrants: Schedule of Stockholders' Equity Note, Warrants or Rights (Details) Sheet http://signpathpharma.com/20140331/role/idr_DisclosureWarrantsScheduleOfStockholdersEquityNoteWarrantsOrRightsDetails Warrants: Schedule of Stockholders' Equity Note, Warrants or Rights (Details) false false R59.htm 000600 - Disclosure - Warrants (Details) Sheet http://signpathpharma.com/20140331/role/idr_DisclosureWarrantsDetails Warrants (Details) false false R60.htm 000610 - Disclosure - Stock Options (Details) Sheet http://signpathpharma.com/20140331/role/idr_DisclosureStockOptionsDetails Stock Options (Details) false false R61.htm 000620 - Disclosure - Note 11 - Income Taxes (Details) Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote11IncomeTaxesDetails Note 11 - Income Taxes (Details) false false R62.htm 000630 - Disclosure - Note 11 - Income Taxes: Schedule of Deferred Tax Assets and Liabilities (Details) Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote11IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails Note 11 - Income Taxes: Schedule of Deferred Tax Assets and Liabilities (Details) false false R63.htm 000640 - Disclosure - Note 11 - Income Taxes: Schedule of Effective Income Tax Rate Reconciliation (Details) Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote11IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails Note 11 - Income Taxes: Schedule of Effective Income Tax Rate Reconciliation (Details) false false R64.htm 000650 - Disclosure - Note 12 - Related Party Transactions (Details) Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote12RelatedPartyTransactionsDetails Note 12 - Related Party Transactions (Details) false false R65.htm 000660 - Disclosure - Note 3 - Summary of Significant Accounting Policies: Fair Value of Financial Instruments: Schedule of derivative instruments (Details) Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote3SummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsScheduleOfDerivativeInstrumentsDetails Note 3 - Summary of Significant Accounting Policies: Fair Value of Financial Instruments: Schedule of derivative instruments (Details) false false R66.htm 000670 - Disclosure - Note 4 - Equipment: ScheduleOfPropertyAndEquipment (Details) Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote4EquipmentScheduleOfPropertyAndEquipmentDetails Note 4 - Equipment: ScheduleOfPropertyAndEquipment (Details) false false R67.htm 000680 - Disclosure - Note 8 - Stock (Details) Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote8StockDetails Note 8 - Stock (Details) false false R68.htm 000690 - Disclosure - Note 9 - Common Stock (Details) Sheet http://signpathpharma.com/20140331/role/idr_DisclosureNote9CommonStockDetails Note 9 - Common Stock (Details) false false All Reports Book All Reports Process Flow-Through: 000020 - Statement - Balance Sheets Process Flow-Through: Removing column 'Mar. 31, 2013' Process Flow-Through: Removing column 'Dec. 31, 2011' Process Flow-Through: Removing column 'Dec. 31, 2010' Process Flow-Through: Removing column 'Dec. 31, 2009' Process Flow-Through: Removing column 'Dec. 31, 2008' Process Flow-Through: Removing column 'Dec. 31, 2007' Process Flow-Through: Removing column 'Dec. 31, 2006' Process Flow-Through: 000030 - Statement - Balance Sheets Parenthetical Process Flow-Through: 000040 - Statement - Statements of Operations Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2011' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2010' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2009' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2008' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2007' Process Flow-Through: 000070 - Statement - Statements of Cash Flows sppxbrl-20140331.xml sppxbrl-20140331.xsd sppxbrl-20140331_cal.xml sppxbrl-20140331_def.xml sppxbrl-20140331_lab.xml sppxbrl-20140331_pre.xml true true